Sexcord/ stromal ovarian tumors screening: Difference between revisions
| Line 15: | Line 15: | ||
According to the [guideline name], screening for [disease name] by [test 1] is recommended every [duration] among patients with [condition 1], [condition 2], and [condition 3]. | According to the [guideline name], screening for [disease name] by [test 1] is recommended every [duration] among patients with [condition 1], [condition 2], and [condition 3]. | ||
==Screening== | ==Screening== | ||
*The US Preventive Services Task Force(USPSTF) recommends against screening for ovarian cancer in asymptomatic women | *The US Preventive Services Task Force(USPSTF) recommends against screening for ovarian cancer in asymptomatic women<ref name="GrossmanCurry2018">{{cite journal|last1=Grossman|first1=David C.|last2=Curry|first2=Susan J.|last3=Owens|first3=Douglas K.|last4=Barry|first4=Michael J.|last5=Davidson|first5=Karina W.|last6=Doubeni|first6=Chyke A.|last7=Epling|first7=John W.|last8=Kemper|first8=Alex R.|last9=Krist|first9=Alex H.|last10=Kurth|first10=Ann E.|last11=Landefeld|first11=C. Seth|last12=Mangione|first12=Carol M.|last13=Phipps|first13=Maureen G.|last14=Silverstein|first14=Michael|last15=Simon|first15=Melissa A.|last16=Tseng|first16=Chien-Wen|title=Screening for Ovarian Cancer|journal=JAMA|volume=319|issue=6|year=2018|pages=588|issn=0098-7484|doi=10.1001/jama.2017.21926}}</ref> | ||
*The USPSTF found that screening with either transvaginal ultrasound or testing for the serum tumor marker cancer antigen 125 (CA-125) or a combination of both does not reduce ovarian cancer mortality | *The USPSTF found that screening with either transvaginal ultrasound or testing for the serum tumor marker cancer antigen 125 (CA-125) or a combination of both does not reduce ovarian cancer mortality | ||
Revision as of 23:20, 31 March 2019
|
Sexcord/ stromal ovarian tumors Microchapters |
|
Differentiating Sexcord/ Stromal Ovarian Tumors from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Sexcord/ stromal ovarian tumors screening On the Web |
|
American Roentgen Ray Society Images of Sexcord/ stromal ovarian tumors screening |
|
Risk calculators and risk factors for Sexcord/ stromal ovarian tumors screening |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:
Overview
There is insufficient evidence to recommend routine screening for [disease/malignancy].
OR
According to the [guideline name], screening for [disease name] is not recommended.
OR
According to the [guideline name], screening for [disease name] by [test 1] is recommended every [duration] among patients with [condition 1], [condition 2], and [condition 3].
Screening
- The US Preventive Services Task Force(USPSTF) recommends against screening for ovarian cancer in asymptomatic women[1]
- The USPSTF found that screening with either transvaginal ultrasound or testing for the serum tumor marker cancer antigen 125 (CA-125) or a combination of both does not reduce ovarian cancer mortality
References
- ↑ Grossman, David C.; Curry, Susan J.; Owens, Douglas K.; Barry, Michael J.; Davidson, Karina W.; Doubeni, Chyke A.; Epling, John W.; Kemper, Alex R.; Krist, Alex H.; Kurth, Ann E.; Landefeld, C. Seth; Mangione, Carol M.; Phipps, Maureen G.; Silverstein, Michael; Simon, Melissa A.; Tseng, Chien-Wen (2018). "Screening for Ovarian Cancer". JAMA. 319 (6): 588. doi:10.1001/jama.2017.21926. ISSN 0098-7484.